In addition to virus exposure, there is an urgent need to better understand the levels and duration of protective immunity for public health considerations. Research in saliva has identified that SARS-CoV-2 antibody testing could serve as a sensitive and specific serum alternative for large scale immune-surveillance studies (1). Importantly, IgG in saliva is derived from serum, so specificity and reactivity of salivary IgG directly reflects serum IgG reactivity, making oral fluid an attractive alternative sample to blood for serological studies (2, 3).
Current research has shown that antibody levels decrease in the serum of COVID-19 patients over time (4) and vary depending on disease severity. In fact, a higher number of asymptomatic participants become seronegative at 60 days indicating a true decline over a 2-month period rather than an artifact of assay performance. Due to this, the current assay has been benchmarked to a serum specific anti-N protein assay instead of PCR assay results.
|Analyte:||SARS-CoV-2 Nucleocapsid Protein IgG|
|Aliases:||COVID-19 Antibody, 2019-nCoV Antibodies, coronavirus Antibodies|
|Optimum Collection Volume:||200 μL*|
How to Collect Saliva
SARS-CoV-2 (N-Protein) IgG SALIVA COLLECTION CONSIDERATIONS
Better results begin with better saliva collection. This collection protocol features general considerations to maximize salivary analysis. Use this analyte-specific collection protocol to plan your collection methodology and sampling schemes.
APPROVED SALIVARY SARS-CoV-2 (N-PROTEIN) IgG COLLECTION METHODS
References & Salivary SARS-CoV-2 Research
- Randad, PR., et al. (2020). COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva. medRxiv.
- Hettegger, P., et al. (2019). High similarity of IgG antibody profiles in blood and saliva opens opportunities for saliva based serology. PloS one. 2019;14(6):e0218456.
- Heaney, JLJ., et al. (2018). The utility of saliva for the assessment of anti-pneumococcal antibodies: investigation of saliva as a marker of antibody status in serum Biomarkers. 23(2):115-22.
- Patel, M., et al. (2020). Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee. JAMA.
- Vabret N. (2020). Antibody responses to SARS-CoV-2 short-lived. Nat Rev Immunol. 20(9):519.
- Long QX., et al. (2020). Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 26(6):845-8.